Scancell Holdings plc (LON:SCLP - Get Free Report)'s share price traded up 28.3% during mid-day trading on Monday . The stock traded as high as GBX 10.87 ($0.14) and last traded at GBX 10.87 ($0.14). 7,645,821 shares changed hands during mid-day trading, an increase of 791% from the average session volume of 858,372 shares. The stock had previously closed at GBX 8.48 ($0.11).
Scancell Stock Performance
The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The firm has a market cap of £109.27 million, a P/E ratio of -16.18 and a beta of 0.35. The stock's 50 day moving average is GBX 8.58 and its two-hundred day moving average is GBX 10.80.
Scancell (LON:SCLP - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. As a group, equities analysts predict that Scancell Holdings plc will post -2.5361112 EPS for the current year.
About Scancell
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
Featured Stories
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
